Abstract: The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making said TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).
Type:
Grant
Filed:
December 22, 2016
Date of Patent:
November 29, 2022
Assignees:
COUR PHARMACEUTICALS DEVELOPMENT COMPANY INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventors:
Ryan Pearson, Daniel Getts, John Puisis, James Herrmann, Lonnie D. Shea
Abstract: The present disclosure is directed to a method of preparing a pharmaceutical composition comprising tolerizing immune-modulating particles of polymer-encapsulated gliadin.
Type:
Grant
Filed:
February 21, 2017
Date of Patent:
November 1, 2022
Assignee:
COUR PHARMACEUTICALS DEVELOPMENT COMPANY, INC.
Inventors:
Daniel R. Getts, Frank Fokta, Ryan Pearson
Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.
Type:
Grant
Filed:
November 2, 2016
Date of Patent:
March 20, 2018
Assignee:
COUR PHARMACEUTICALS DEVELOPMENT COMPANY, INC.